Spots Global Cancer Trial Database for melphalan
Every month we try and update this database with for melphalan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT03691376 | Platinum-Resist... Platinum-Resist... Platinum-Resist... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Refractory Fall... Refractory Ovar... Refractory Prim... | Aldesleukin Autologous NY-E... Cellular Therap... Melphalan | 18 Years - | Roswell Park Cancer Institute | |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma | NCT02043860 | Multiple Myelom... | Total Marrow Ir... Autologous Tran... Melphalan Filgrastim (G-C... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma | NCT00907036 | Lymphoma | alemtuzumab donor lymphocyt... cyclosporine fludarabine pho... melphalan allogeneic hema... | 16 Years - 65 Years | National Cancer Institute (NCI) | |
| Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | NCT01476839 | Recurrent Adult... | basiliximab carmustine etoposide cytarabine melphalan pharmacological... laboratory biom... autologous hema... yttrium Y 90-la... | 18 Years - 70 Years | City of Hope Medical Center | |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | NCT02333162 | Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat... | Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom... | 18 Years - 75 Years | University of Chicago | |
| Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | NCT01658904 | Multiple Myelom... Leukemia, Plasm... | Carfilzomib Melphalan Filgrastim | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma | NCT00901238 | Retinoblastoma | Intra-arterial ... | 1 Month - | Weill Medical College of Cornell University | |
| Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | NCT02909036 | Multiple Myelom... Amyloidosis | Melphalan Pegfilgrastim Autologous Hema... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma | NCT02415036 | Hepatocellular ... Intrahepatic Ch... | Delcath Hepatic... Melphalan | 18 Years - | Delcath Systems Inc. | |
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | NCT00936936 | Testicular Canc... | Gemcitabine Docetaxel Melphalan Carboplatin Mesna Ifosfamide Etoposide Stem Cell Trans... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma | NCT00244946 | Lymphoma | therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo... | 15 Years - 70 Years | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis | NCT03118492 | Secondary Myelo... | Allogeneic Hema... Cyclophosphamid... Fludarabine Glycosylated Re... Laboratory Biom... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra... | 18 Years - 65 Years | City of Hope Medical Center | |
| Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00550784 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | filgrastim cisplatin cyclophosphamid... melphalan paclitaxel topotecan hydro... TdT-mediated dU... gene expression... immunohistochem... pharmacological... peripheral bloo... | - 60 Years | City of Hope Medical Center | |
| Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy | NCT00205764 | Multiple Myelom... | Melphalan | 19 Years - 70 Years | Austrian Forum Against Cancer | |
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | NCT00807599 | Multiple Myelom... | Stem cell trans... lenalidomide an... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma | NCT00482846 | Mucositis Multiple Myelom... | Palifermin melphalan questionnaire a... autologous peri... quality-of-life... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | NCT00325416 | Multiple Myelom... | melphalan topotecan (TPT) Autologous Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor | NCT01598025 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Non-Hodgkins Ly... | total-body irra... thiotepa fludarabine pho... melphalan anti-thymocyte ... allogeneic hema... peripheral bloo... laboratory biom... | - 19 Years | Memorial Sloan Kettering Cancer Center | |
| MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning | NCT00564200 | Multiple Myelom... | Bortezomib dexamethasone Fludarabine Melphalan | 18 Years - 66 Years | PETHEMA Foundation | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | NCT00357565 | Leukemia Myelodysplastic... Childhood Acute... Recurrent Child... Secondary Acute... Childhood Acute... Previously Trea... Secondary Myelo... Refractory Anem... Refractory Anem... Refractory Anem... De Novo Myelody... Childhood Myelo... | filgrastim busulfan cyclosporine fludarabine pho... melphalan mycophenolate m... umbilical cord ... | - 3 Years | Masonic Cancer Center, University of Minnesota | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas | NCT00043979 | Sarcoma | F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo... | 5 Years - 35 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies | NCT00824135 | Hematologic Mal... | Clofarabine Stem Cell Trans... OKT3 Thiotepa Melphalan Mycophenolate m... Rituximab G-CSF | - 21 Years | St. Jude Children's Research Hospital | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors | NCT01342237 | Brain Tumors | HDCT 1(TTC), HD... | - | Seoul National University Hospital | |
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | NCT00303849 | Anaplastic Olig... Anaplastic Olig... Mixed Glioma Oligoastrocytom... | Carboplatin Etoposide Etoposide Phosp... Laboratory Biom... Mannitol Melphalan Quality-of-Life... Sodium Thiosulf... | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer | NCT00002680 | Breast Cancer | filgrastim cyclophosphamid... megestrol aceta... melphalan tamoxifen citra... thiotepa conventional su... peripheral bloo... radiation thera... | 18 Years - | Yale University | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| HD Melphalan and SCT in Patients With IGDD or LCDD | NCT00681044 | Multiple Myelom... | filgrastim melphalan Stem Cell Infus... | 18 Years - 120 Years | Boston Medical Center | |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | NCT02528877 | Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo... | Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | NCT01341262 | Multiple Myelom... | Thalidomide Dexamethasone Zoledronic acid Cyclophosphamid... Melphalan | 18 Years - 65 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor | NCT02784054 | Intracranial No... | Carboplatin Etoposide Cyclophosphamid... Bleomycin Thiotepa Melphalan Reduced dose ra... | 3 Years - 30 Years | Samsung Medical Center | |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma | NCT00504101 | Multiple Myelom... | Arsenic trioxid... Bortezomib Melphalan Autologous hema... | 18 Years - 70 Years | University of Miami | |
| Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00007852 | Lymphoma | rituximab carmustine cytarabine etoposide melphalan autologous hema... | 19 Years - | University of Nebraska | |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation | NCT04339101 | Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo... | Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus | 18 Years - 75 Years | City of Hope Medical Center | |
| Topotecan and Melphalan for Retinoblastoma | NCT04799002 | Retinoblastoma Chemotherapy Ef... | Topotecan Melphalan | - | Sun Yat-sen University | |
| Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | NCT00567567 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Doxorubicin Hyd... Etoposide External Beam R... Filgrastim Isotretinoin Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Thiotepa Topotecan Hydro... Vincristine Sul... | - 30 Years | Children's Oncology Group | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma | NCT00901238 | Retinoblastoma | Intra-arterial ... | 1 Month - | Weill Medical College of Cornell University | |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03019640 | Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo... | Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab | 15 Years - 70 Years | M.D. Anderson Cancer Center | |
| Nivolumab With Chemotherapy in Refractory MDS | NCT03259516 | Myelodysplastic... | Nivolumab Azacitidine Fludarabine Cyclophosphamid... Cytarabine all trans retin... Sildenafil Melphalan | 18 Years - 80 Years | St. Petersburg State Pavlov Medical University | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | NCT03259503 | Recurrent Diffu... Recurrent T-Cel... Refractory Diff... Refractory Hodg... Refractory T-Ce... | Busulfan Gemcitabine Melphalan Olaparib Peripheral Bloo... Pharmacokinetic... Rituximab Vorinostat | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | NCT00075608 | Multiple Myelom... Plasma Cell Neo... | filgrastim melphalan autologous stem... stem cell infus... | 18 Years - 65 Years | Boston Medical Center | |
| Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | NCT00539500 | Neuroblastoma | Carboplatin Etoposide Melphalan Stem Cell Infus... ClinicMACS | - | M.D. Anderson Cancer Center | |
| Stem Cell Transplantation for Hematological Malignancies | NCT00176839 | Leukemia, Lymph... AML MDS | Stem Cell Trans... Busulfan Cyclophosphamid... Melphalan G-CSF ATG | - 35 Years | Masonic Cancer Center, University of Minnesota | |
| Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | NCT00477035 | Leukemia Multiple Myelom... | CIK cells etoposide bcnu cyclophosphamid... gemcitabine vinorelbine melphalan | 18 Years - 75 Years | Stanford University | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome | NCT05617625 | Myelodysplastic... Graft Vs Host D... Graft-versus-ho... | Busulfan Melphalan Fludarabine CliniMACS CD34+... | 18 Years - 75 Years | Baptist Health South Florida | |
| Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis | NCT01383759 | Light Chain Dep... Light Chain and... Monoclonal Immu... Amyloidosis | Bortezomib/Dexa... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor | NCT02784054 | Intracranial No... | Carboplatin Etoposide Cyclophosphamid... Bleomycin Thiotepa Melphalan Reduced dose ra... | 3 Years - 30 Years | Samsung Medical Center | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00040937 | Multiple Myelom... | filgrastim sargramostim cyclophosphamid... dexamethasone melphalan prednisone thalidomide peripheral bloo... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| URMC Related Haplo-identical Donor BMT | NCT02660281 | Hematological D... Immune Deficien... Solid Tumors Myelofibrosis Multiple Myelom... Lymphoma | Total Body Irra... Fludarabine Pre-Stem Cell I... Pre-Stem Cell I... Busulfan Melphalan Stem Cell Infus... Post-Stem Cell ... Post-Stem Cell ... Thiotepa | 6 Months - 75 Years | University of Rochester | |
| BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma | NCT03794167 | Non-hodgkin Lym... | Busulfan Cyclophosphamid... Etoposide Melphalan | 18 Years - 65 Years | Soonchunhyang University Hospital | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma | NCT00566098 | Multiple Myelom... | MILs Melphalan PCV13 | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | NCT00968396 | Multiple Myelom... | Apheresis Stem Cell Trans... Melphalan | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Haplo Peripheral Blood Sct In GVHD Prevention | NCT04473911 | GVHD AML ALL MDS MPN CMML Hodgkin Lymphom... Non Hodgkin Lym... Blood Stem Cell... Graft Vs Host D... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myelomo... Chemosensitive ... | FLUDARABINE CYCLOPHOSPHAMID... TBI Melphalan Sirolimus Mycophenolate m... RGI-2001 CYCLOPHOSPHAMID... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00602641 | Multiple Myelom... | Laboratory Biom... Lenalidomide Melphalan Prednisone Quality-of-Life... Thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients | NCT00661544 | Multiple Myelom... Stem Cell Trans... | Arsenic Trioxid... Melphalan Ascorbic Acid | - 70 Years | M.D. Anderson Cancer Center | |
| Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | NCT01824693 | Juvenile Myelom... | Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Pharmacological... Tacrolimus | 3 Months - 18 Years | Children's Oncology Group | |
| 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) | NCT03003728 | Multiple Myelom... | Elotuzumab Melphalan Autologous Stem... Expanded Natura... ALT-803 | 18 Years - 75 Years | University of Arkansas | |
| Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma | NCT00410631 | Neuroblastoma | filgrastim carboplatin cisplatin cyclophosphamid... dacarbazine doxorubicin hyd... etoposide phosp... ifosfamide isotretinoin melphalan topotecan hydro... vincristine sul... vindesine autologous hema... conventional su... peripheral bloo... iobenguane I 13... radiation thera... | - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia | NCT00008190 | Leukemia | aldesleukin filgrastim busulfan cyclophosphamid... etoposide melphalan peripheral bloo... | - | National Cancer Institute (NCI) | |
| Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy | NCT01807611 | Leukemia Lymphoma | Total Lymphoid ... Fludarabine Cyclophosphamid... Thiotepa Melphalan HPC,A Infusion TC-NK Infusion G-CSF Mesna CliniMACS Mycophenolate m... | - 21 Years | St. Jude Children's Research Hospital | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| ASCT With Nivolumab in Patients With Multiple Myeloma | NCT03292263 | Multiple Myelom... | Melphalan Nivolumab Autologous Stem... | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Microdose Study of Melphalan, Bortezomib and Dexamethasone | NCT02109861 | Multiple Myelom... | Melphalan Bortezomib Dexamethasone | 18 Years - | Aalborg University Hospital | |
| Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis | NCT00344526 | Primary Systemi... | Melphalan Dexamethasone Autologous stem... | 18 Years - 70 Years | University Hospital, Limoges | |
| Combination Chemotherapy in Treating Patients With Lymphoma | NCT00002835 | Lymphoma | Bleomycin Sulfa... Filgrastim (G-C... Recombinant Int... Carmustine Cisplatin (CDDP... Cyclophosphamid... Cytarabine (ARA... Etoposide (VP-1... Idarubicin Ifosfamide Leucovorin Calc... Melphalan Methotrexate Methylprednisol... mitoxantrone hy... Vincristine Sul... Peripheral Bloo... Radiation Thera... | 15 Years - 59 Years | M.D. Anderson Cancer Center | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | NCT03393611 | Myelodysplastic... Leukemia, Myelo... Leukemia, Relap... Myelodysplastic... | CPX-351 Fludarabine Melphalan Rabbit Anti-Hum... Haplo-Cord Stem... | 18 Years - 89 Years | Weill Medical College of Cornell University | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment | NCT03234335 | Multiple Myelom... Renal Failure | Data collection | 66 Years - | Centre Hospitalier Universitaire de Saint Etienne | |
| Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | NCT00004165 | Multiple Myelom... | filgrastim melphalan peripheral bloo... | - | Northwestern University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
